Currently, three specific HER2-targeting antibodies, trastuzumab (HerceptinTM), pertuzumab (PerjetaTM), and T-DM1 (KadcylaTM), are widely used to treat HER2-positive breast cancer patients [5]. Here, ERBB2 is linked to breast carcinoma.